Patents by Inventor Aliza Eshkol
Aliza Eshkol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7803760Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: GrantFiled: April 21, 2008Date of Patent: September 28, 2010Assignee: Merck Serono SAInventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
-
Patent number: 7507707Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: GrantFiled: December 14, 2001Date of Patent: March 24, 2009Assignee: Laboratoires Serono SAInventors: Stephen Palmer, Mark Tepper, Sean McKenna, Michael C. MacNamee, Aliza Eshkol
-
Publication number: 20080293622Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: ApplicationFiled: April 21, 2008Publication date: November 27, 2008Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. Macnamee
-
Publication number: 20080213889Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: ApplicationFiled: November 9, 2007Publication date: September 4, 2008Inventors: Stephen S. Palmer, Sean D. McKenna, Stephen J. Arkinstall, Aliza Eshkol, Michael C. MacNamee
-
Patent number: 7364910Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: GrantFiled: July 6, 2006Date of Patent: April 29, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20060293222Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: ApplicationFiled: July 6, 2006Publication date: December 28, 2006Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael MacNamee
-
Patent number: 7153824Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: GrantFiled: April 1, 2004Date of Patent: December 26, 2006Assignee: Applied Research Systems ARS Holding N.V.Inventors: Stephen S. Palmer, Sean D. McKenna, Stephen J. Arkinstall, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20060229288Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: ApplicationFiled: February 28, 2006Publication date: October 12, 2006Inventors: STEPHEN PALMER, SEAN McKENNA, STEPHEN ARKINSTALL, ALIZA ESHKOL, MICHAEL MacNAMEE
-
Patent number: 7078236Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: GrantFiled: June 28, 2005Date of Patent: July 18, 2006Assignee: Applied Research Systems ARS Holding N.V.Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20060003925Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: ApplicationFiled: June 28, 2005Publication date: January 5, 2006Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael MacNamee
-
Patent number: 6953774Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase type 4.Type: GrantFiled: December 14, 2001Date of Patent: October 11, 2005Assignee: Applied Research Systems Ars Holding N.V.Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20050148501Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: ApplicationFiled: December 14, 2001Publication date: July 7, 2005Inventors: Stephen Palmer, Mark Tepper, Sean Mckenna, Michael Macnamee, Aliza Eshkol
-
Publication number: 20050079156Abstract: The present invention relates to the treatment of a woman for endometriosis comprising the administration of IFN-gamma, a cytokine antagonist and/or an anti-estrogenic agent.Type: ApplicationFiled: October 29, 2002Publication date: April 14, 2005Inventors: Grace Wong, Aliza Eshkol
-
Publication number: 20050002900Abstract: The present invention is directed to a method of treating estrogen responsive breast cancer in an individual comprising administering to an individual a therapeutically effective estradiol inhibiting amount of interferon gamma (IFN-?) and/for a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists. The invention is based upon the surprising discovery that IFN-? and/or a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists inhibit estradiol production in human adipocytes. This discovery is not only important because it allows for the treatment and/or prevention of estrogen dependent breast cancer using IFN-?, TNF antagonists or IL-1 antagonist each alone or in combination, but also because IFN-? and/or TNF antagonists and/or IL-1 antagonists can be used in conjunction with standard anti-estrogen therapy, e.g., tamoxifen and/or aromatase inhibitor, to result in lower estrogen levels than seen with standard anti-estrogen therapy alone.Type: ApplicationFiled: November 5, 2002Publication date: January 6, 2005Inventors: Grace Wong, Aliza Eshkol, Giampiero DeLuca
-
Publication number: 20040259792Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: ApplicationFiled: April 1, 2004Publication date: December 23, 2004Inventors: Stephen S. Palmer, Sean D. McKenna, Stephen J. Arkinstall, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20020103106Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: ApplicationFiled: December 14, 2001Publication date: August 1, 2002Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. Macnamee
-
Publication number: 20020065324Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: ApplicationFiled: August 10, 2001Publication date: May 30, 2002Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. Macnamee
-
Patent number: 4521407Abstract: The cellular immune system of a person having acquired immune deficiency syndrome is stimulated by administering an immunopotentiating effective amount of a calf thymus extract to such person, the extract showing, upon electrophoresis on polyacrylamide gel at pH 8.6 two main characteristic bands with an Rf of about 0.25 and 0.44.Type: GrantFiled: August 29, 1983Date of Patent: June 4, 1985Assignee: Serono Pharmaceutical PartnersInventors: Russell W. Pelham, Charlotte S. Redden, Aliza Eshkol, Gerald E. Stiles